Core Viewpoint - Butterfly Network, Inc. (BFLY) has been upgraded to a Zacks Rank 2 (Buy), indicating an upward trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with near-term stock price movements [4][6]. - Rising earnings estimates for Butterfly Network suggest an improvement in the company's underlying business, likely leading to an increase in stock price [5][10]. Zacks Rating System - The Zacks Rank stock-rating system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly Zacks Rank 1 stocks averaging a +25% annual return since 1988 [7][9]. - The upgrade of Butterfly Network to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10]. Earnings Estimate Revisions - Analysts have raised their earnings estimates for Butterfly Network, with the Zacks Consensus Estimate increasing by 7.5% over the past three months [8]. - The company is expected to earn -$0.25 per share for the fiscal year ending December 2025, showing no year-over-year change [8].

Butterfly Network (BFLY -5.25%), a medical device company known for its portable ultrasound technology, released its second quarter fiscal 2025 results on August 1, 2025. The headline news: it delivered a record gross margin of 63.7% (GAAP), narrowed its losses, and grew revenue by 9.0% compared to Q2 2024. However, revenue (GAAP) came in at $23.4 million, slightly shy of the $23.72 million projected by analysts. Non-GAAP earnings per share were $(0.03), better than the expected $(0.05) (adjusted). Manageme ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Table of Contents Washington, D.C. 20549 ____________________________________________ FORM 10-Q ____________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to Commission File Number: 001-39292 ___ ...

Financial Data and Key Metrics Changes - The company reported record revenue of $23.4 million for Q2 2025, representing a 9% increase compared to the previous year, driven by higher average selling prices and sales of semiconductor chips [16][20] - Gross margins reached an all-time high of 64%, up from 59% in the prior year, attributed to higher average selling prices and improved software and services margins [20] - Adjusted EBITDA loss improved to $6.2 million from $8.1 million in the same period last year, reflecting a 24% improvement [20][24] Business Line Data and Key Metrics Changes - Product revenue was $16.6 million, a 13% increase year-over-year, primarily due to higher average selling prices and chip sales [18] - Software and other services revenue remained flat at $6.8 million, impacted by lower renewals of individual subscriptions and implementation services revenue [19] - Total Annual Recurring Revenue (ARR) grew slightly, led by an increase in enterprise software subscription ARR [19] Market Data and Key Metrics Changes - U.S. revenue was $17.2 million, essentially flat year-over-year, affected by lower probe volume despite higher average selling prices [17] - International revenue increased by 19% to $6.2 million, driven by the international launch of iQ3 and geographic expansion [17] Company Strategy and Development Direction - The company is focusing on larger deals and expanding its enterprise and medical school pipeline, despite delays in closing some larger deals [6][22] - The launch of the next-generation software platform, Compass AI, is expected to enhance documentation processes and improve enterprise sales [27][28] - The company is optimistic about the long-term growth potential of handheld ultrasound technology and its ability to drive worldwide adoption [34] Management's Comments on Operating Environment and Future Outlook - Management noted macroeconomic headwinds affecting purchase decisions, particularly in the U.S. hospital and enterprise channels [22][60] - The company has adjusted its full-year revenue guidance to a range of $91 million to $95 million, reflecting the need to close delayed larger deals [23][24] - Management remains confident in the company's value proposition and believes it will thrive in a cost-contained healthcare environment [5][34] Other Important Information - The company announced the departure of its CFO, Heather Gatz, who will transition to an advisory role until early 2026 [13][15] - The Butterfly Garden initiative is entering its commercial phase, with new AI tools expected to enhance clinical use [9][11] Q&A Session Summary Question: Competitive landscape and headwinds - Management clarified that the guidance revision was not due to competition but rather delays in larger deals, emphasizing that they are pioneering new market segments [36][38] Question: Software subscription revenue trends - Management indicated that individual subscription renewals face challenges, while enterprise software is growing, aided by the upcoming Compass AI [42][44] Question: Guidance assumptions and enterprise side impact - Management noted that delays in global health deals and enterprise sales have led to a conservative guidance adjustment, but they remain optimistic about future opportunities [54][56] Question: Home care pilot program details - Management shared that the home care program has shown significant reductions in readmissions, and they are working to finalize commercial agreements [65][67] Question: IQ Station and P5 updates - Management confirmed that IQ Station will compete with existing ultrasound carts, and the P5 technology is expected to significantly enhance image quality [91][93]

Butterfly Network, Inc. (BFLY) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.05 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +14.29%. A quarter ago, it was expected that this company would post a loss of $0.09 per share when it actually produced a loss of $0.06, delivering a surprise of +33.33%.Over the last four quarters, the company ...

Exhibit 99.1 Delivered Highest Quarterly Revenue and Gross Margins in Company History BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE) -- Butterfly Network, Inc. (NYSE: BFLY) ("Butterfly" or the "Company"), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, today announced financial results for the second quarter ended June 30, 2025, and provided a business update. Joseph DeVivo, Butterfly's President, Chief Executive Officer and Chairman ...

Butterfly Network (BFLY) FY Conference Summary Company Overview - Butterfly Network is focused on revolutionizing medical imaging, particularly ultrasound technology, by making it more accessible and cost-effective through semiconductor innovations [8][9][21] Industry Insights - The ultrasound market is projected to grow significantly, with the core point-of-care ultrasound market estimated at $600 million and the broader market potentially reaching $8 billion [50] - There is a notable lack of access to medical imaging globally, with two-thirds of the world lacking access to ultrasound [7] Key Financials - The company projects a 20% growth for the year, targeting revenues between $96 million and $100 million, with an EBITDA loss [8] - The first quarter of 2025 saw a revenue of $25 million, reflecting the anticipated growth trajectory [8] Technological Innovations - Butterfly Network utilizes MEMS semiconductor technology, allowing for a compact, cost-effective ultrasound device that can be used by various healthcare professionals [19][21] - The company has launched its third generation of ultrasound devices, with plans for a fourth generation expected by 2026 [39][41] - The device's capabilities are enhanced through a cloud-based software ecosystem, which allows for continuous updates and improvements [25][26] AI Integration - Butterfly has developed AI tools that assist in ultrasound scanning, including automatic bladder volume measurement and lung assessments for congestive heart failure [33] - The company is opening its ecosystem to third-party developers, allowing for the creation of additional AI applications that can be integrated with Butterfly devices [34] Market Position and Strategy - Butterfly Network claims the largest installed base for handheld ultrasound devices, surpassing competitors like GE and Philips [36] - The company is actively pursuing partnerships and licensing opportunities for its semiconductor technology, expanding its market reach beyond healthcare [62][63] Educational Initiatives - Approximately 70% of medical schools in the U.S. are incorporating Butterfly devices into their training programs, fostering a new generation of healthcare professionals skilled in ultrasound [55][56] - The company is developing educational tools to assist students in learning ultrasound techniques, enhancing their practical skills [58][59] Future Outlook - Butterfly Network aims to expand its presence in home healthcare by training nurses to perform ultrasound scans, potentially creating new revenue streams [61] - The company is committed to leveraging its $300 million investment in semiconductor technology to explore opportunities in various sectors, including wearables and non-healthcare applications [63] Conclusion - Butterfly Network is positioned as a disruptive force in the ultrasound market, with a strong focus on innovation, accessibility, and education, aiming to transform how ultrasound technology is utilized in healthcare and beyond [49][50]

Core Viewpoint - Tempus AI and Butterfly Network are two AI-driven healthcare companies that are transforming diagnostics through their innovative approaches, with Tempus focusing on precision oncology and Butterfly on point-of-care imaging [1] Company Performance - Tempus AI's shares have increased by 55.4% over the past year, while Butterfly Network's shares have surged by 114.8%, significantly outperforming the Medical Info Systems industry's gain of 13.6% and the S&P 500's rise of 10.8% [2] Tempus AI Highlights - Revenue Growth and Margin Expansion: Tempus AI reported a 75.4% year-over-year revenue increase in Q1 2025, with its data licensing segment growing by 58%, contributing to overall profitability [6][8] - Positive EBITDA Outlook: The company is on track to achieve adjusted EBITDA profitability in 2025, narrowing its adjusted EBITDA loss to $16.2 million from $43.9 million a year earlier, reflecting strong revenue growth and disciplined spending [7] - Strategic Partnerships and Contract Backlog: Tempus AI secured a $200 million deal with AstraZeneca and Pathos, alongside a remaining contract value of over $1 billion, ensuring predictable revenues and financial stability [8][9] Butterfly Network Highlights - Strong Financial Performance: Butterfly Network achieved 20% year-over-year revenue growth in Q1 2025, with gross margins rising to 63% and adjusted EBITDA loss narrowing to $9.1 million [10] - Diversified Product Portfolio: The company has expanded its offerings under CEO Joseph DeVivo, introducing multiple probes and the Butterfly Garden AI marketplace, which diversifies revenue streams [11] - International Growth: Despite challenges, Butterfly Network's international revenues grew by 9% year-over-year, supported by pricing gains and partnerships with over 800 NGOs [12] Valuation Comparison - Tempus AI has a forward price-to-sales (P/S) ratio of 7.90, while Butterfly Network's ratio is 5.00, indicating that Butterfly is attractively valued compared to the industry average of 5.51 [13] - Analysts suggest a 10.55% upside for Tempus AI based on price targets, while Butterfly Network's average target indicates a potential increase of 94.86% [14][16] Investment Recommendation - Butterfly Network is currently rated a Zacks Rank 2 (Buy), presenting a more compelling investment case compared to Tempus AI, which holds a Zacks Rank 3 (Hold), due to its improving financials and lower valuation [18]

Core Viewpoint - The article emphasizes the importance of investing in high-quality growth and momentum stocks that are reasonably priced, with a focus on long-term performance and market outperformance [1]. Group 1: Investment Strategy - The investment strategy involves focusing on growth and momentum stocks that are expected to outperform the market over the long term [1]. - The analyst has a history of advising investors to buy at market lows, specifically mentioning a recommendation in March 2009 during the financial crisis, which led to significant market gains [1]. Group 2: Market Performance - From 2009 to 2019, the S&P 500 increased by 367%, while the Nasdaq saw an increase of 685%, highlighting the potential for substantial returns in the stock market [1]. Group 3: Investor Guidance - The article aims to assist investors in making money through investments in high-quality growth stocks, indicating a commitment to guiding investors towards profitable opportunities [1].

Financial Data and Key Metrics Changes - The company reported a revenue of $21.2 million for Q1 2025, reflecting a 20% growth compared to the previous year [13][14] - Gross profit increased to $13.4 million, a 30% rise from $10.3 million in the prior year, with gross margin improving to 63% from 58% [16] - Adjusted EBITDA loss improved from $13.2 million a year ago to $9.1 million, marking a 31% improvement [16][20] Business Line Data and Key Metrics Changes - Product revenue reached $14.2 million, up 25% year-over-year, driven by higher sales volume [14] - Software and other services revenue was $7.1 million, an 11% increase, attributed to higher enterprise software revenue [15] - The mix of revenue from software and services decreased to 33% as product revenue growth outpaced software revenue [15] Market Data and Key Metrics Changes - U.S. revenue was $16.6 million, a 24% increase year-over-year, while international revenue rose 9% to $4.6 million [14] - The company is focusing on expanding its presence in Asia and Latin America, as well as high-potential global health markets [11] Company Strategy and Development Direction - The company is diversifying its product offerings, including the introduction of the AI marketplace Butterfly Garden and the chip licensing program Octave [5][24] - The company aims to maintain leadership in digital, cloud-connected, open platform, and EMR integrated systems through continued R&D investment [6] - The strategy includes targeting medical schools for personal probe purchases, similar to Apple's approach with laptops [8][9] Management's Comments on Operating Environment and Future Outlook - Management acknowledged economic headwinds, particularly from USAID funding cuts affecting global health initiatives, but remains optimistic about future growth [12][20] - The company expects to maintain its full-year guidance of approximately 20% revenue growth despite uncertainties in healthcare funding [21] - Management emphasized the long-term value of its technology, which is seen as a more affordable solution compared to traditional ultrasound systems [21][22] Other Important Information - The company completed a secondary public offering generating $81 million, which will support ongoing investments and growth initiatives [17] - The upcoming launch of Compass 2.0 software is anticipated to enhance operational efficiency and create new revenue streams [29] Q&A Session Summary Question: Can you discuss the process for securing the second hospital enterprise contract? - Management highlighted the groundswell of demand from doctors for Butterfly technology, leading to institutional adoption and integration into hospital networks [37][40] Question: What is the funnel for additional opportunities with medical schools? - The company is seeing strong interest from medical schools in one-to-one probe programs, with discussions focused on budget allocations for the upcoming fiscal year [42][44] Question: How impactful have the publications from Rochester and Rutgers been on the hospital channel? - The publications have opened conversations at the C-suite level in hospitals, highlighting the widespread adoption of Butterfly technology among affiliated doctors [51][52] Question: What is the split between price and volume in U.S. product sales? - The split is approximately 80% volume and 20% price, with significant price increases observed in international markets [73] Question: How is the company managing currency risks? - The company reported virtually no foreign currency risk, indicating a stable financial position despite currency fluctuations [61]